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The BCL6 transcriptional repressor is required for the
development of germinal center (GC) B cells and
diffuse large B cell lymphomas (DLBCLs). Although
BCL6 can recruit multiple corepressors, its transcrip-
tional repression mechanism of action in normal and
malignant B cells is unknown. We find that in B cells,
BCL6 mostly functions through two independent
mechanisms that are collectively essential to GC for-
mation and DLBCL, both mediated through its N-ter-
minal BTB domain. These are (1) the formation of a
unique ternary BCOR-SMRT complex at promoters,
with each corepressor binding to symmetrical sites
on BCL6 homodimers linked to specific epigenetic
chromatin features, and (2) the ‘‘toggling’’ of active
enhancers to a poised but not erased conforma-
tion through SMRT-dependent H3K27 deacetylation,
which is mediated by HDAC3 and opposed by p300
histone acetyltransferase. Dynamic toggling of en-
hancers provides a basis for B cells to undergo rapid
transcriptional and phenotypic changes in response
to signaling or environmental cues.
INTRODUCTION
The BCL6 transcriptional repressor is required for formation
of germinal centers (GCs) during T cell-dependent immune
responses (Ci et al., 2008). BCL6 also plays a critical role in initi-578 Cell Reports 4, 578–588, August 15, 2013 ª2013 The Authorsation and maintenance of B cell lymphomas derived from GC
B cells such as diffuse large B cell lymphomas (DLBCLs)
(Ci et al., 2008). Defining the mechanism of action of BCL6 is
of crucial importance to understanding the biology of B cells
and the molecular pathogenesis of BCL6-dependent lymphoid
neoplasms. BCL6 is a member of the BTB-POZ C2H2 zinc finger
family of transcription factors (Stogios et al., 2005). The BCL6
BTB domain has autonomous repressor activity and folds as
an obligate homodimer (Ahmad et al., 2003). The dimer interface
forms two extended grooves that serve as docking sites for three
corepressors: SMRT, NCOR, and BCOR (Ahmad et al., 2003;
Ghetu et al., 2008). SMRT and NCOR are highly conserved and
bind to the BCL6 BTB groove with an identical peptide
sequence. They form a complex with TBL1, TBLR1, GPS2, and
HDAC3 and allosterically enhance HDAC3-mediated H3K9 acet-
ylation (Karagianni andWong, 2007). BCOR shares no sequence
or structure similarity with SMRT/NCORand binds to BCL6 using
a completely different peptide sequence (Ahmad et al., 2003;
Ghetu et al., 2008). BCOR forms a Polycomb repressor com-
plex 1 (PRC1)-like complex with PCGF1, KDM2B, RING1,
SKP1, RYBP, and RNF2 (Farcas et al., 2012; Gao et al., 2012;
Gearhart et al., 2006; Sa´nchez et al., 2007). BTB point mutations
that disrupt corepressor recruitment inactivate BTB domain
repressor function (Ahmad et al., 2003; Ghetu et al., 2008). A
similar effect can be achieved using specific BCL6 BTB groove
binding peptides or small molecules (Cerchietti et al., 2009,
2010a; Polo et al., 2004). The BTB domain corepressor interac-
tion is an important mediator of BCL6 actions and a potential
therapeutic target (Ci et al., 2008; Parekh et al., 2008), yet it is
not known how these protein interactions translate into tran-
scriptional repression and where and how different BCL6
complexes assemble in the genome. Herein, we confirm that
BTB-corepressor interactions are absolutely required for survival
of both malignant and normal B cells. We show that BCL6 medi-
ates these effects through two functionally distinct mechanisms.
The first involves formation of a unique ternary complex whereby
BCL6 can coordinate the actions of the BCOR Polycomb-like
complex with SMRT/NCOR to potently repress target genes.
The second involves a mechanism for ‘‘toggling’’ active en-
hancers into a ‘‘poised’’ configuration through SMRT-HDAC3-
dependent H3K27 deacetylation. This function for HDAC3
enables BCL6-SMRT complexes to compete with p300 in
switching enhancers between ‘‘on’’ and ‘‘off’’ states. Reversible
enhancer toggling may be critical for dynamic modulation of the
BCL6 transcriptional program during the GC reaction as well for
the therapeutic effects of BCL6 inhibitors.
RESULTS
Distinct Genomic Localization Patterns of Specific
BCL6-Corepressor Complexes
To evaluate the full impact of disrupting BCL6 BTB domain inter-
actions with corepressors in DLBCL cells, we treated mice
bearing human DLBCL cell line xenografts with RI-BPI, a pepti-
domimetic that specifically disrupts the BCL6 BTB domain inter-
action with SMRT, NCOR, and BCOR corepressors (Cerchietti
et al., 2009; Polo et al., 2004). Low doses of RI-BPI (25 mg/kg/
day) given to mice were shown to slow DLBCL tumor growth
(Cerchietti et al., 2009). In the current study, we administered
RI-BPI (50 mg/kg) or control peptide for 5 days to mice bearing
established human DLBCL xenografts. RI-BPI caused complete
regression of fully established DLBCL tumors in 100% of mice
(Figure 1A). There was no microscopic evidence of residual
tumor or tumor regrowth after treatment discontinuation in
60% of these mice. Hence, the BCL6 BTB domain corepressor
recruitment is essential for the survival of BCL6-dependent
human DLBCL cells. To dissect out the transcriptional mecha-
nisms through which BCL6 and its corepressors mediate these
essential functions, we next performed chromatin immunopre-
cipitation sequencing (ChIP-seq) for these proteins in DLBCL
cells (OCI-Ly1). All ChIP-seq assaysmet ENCODE quality criteria
(Table S1). Using stringent peak detection thresholds and the
overlap of two highly correlated biological replicates (r = 0.84),
we identified 14,780 BCL6 binding sites corresponding to the
most highly enriched peaks (Figures S1A and S1B). Most BCL6
peaks localized to intronic (42%) and intergenic regions (31%),
whereas 23% located to promoters (Figure 1B). The BCL6
DNA binding motif (Ci et al., 2009) was highly overrepresented
(p < 1 3 108) and preferentially localized near the BCL6 peak
summits (Figure S1C). BCL6 was enriched at well-known BCL6
targets such as BCL6 itself (Wang et al., 2002), PRDM1 (Shaffer
et al., 2000), TP53 (Phan and Dalla-Favera, 2004), EP300
(Cerchietti et al., 2010b), BCL2 (Ci et al., 2009; Saito et al.,
2009), and ATR (Ranuncolo et al., 2007) (Figure S1D).
Our ChIP-seq analysis of BCL6 corepressors identified 4,379
SMRT, 4,302 NCOR, and 17,548 BCOR high-quality peaks (Fig-
ures S1E, S1F, and S2A). Strikingly 90% of SMRT and NCOR
peaks overlapped with BCL6, suggesting that their function is
mostly tied to BCL6 in DLBCL (Figures 1C andS2A). Even thoughNCOR and SMRT can bind to many transcription factor partners
(Perissi et al., 2010), it appears that association with BCL6 is their
dominant function in the B cell context. Reciprocally, only 27%of
BCL6 peaks were occupied by NCOR-SMRT. BCL6-SMRT and
BCL6-NCOR complexes exhibit extensive binding in intergenic
and intronic regions with proportionally less promoter binding
(Figure 1B). Because SMRT and NCOR were mostly colocalized
and have similar biochemical functions (r = 0.76, Pearson; Fig-
ure S1E), we focused on SMRT for subsequent analyses.
BCOR occupied 36% of BCL6 peaks and was more widely
distributed to non-BCL6-containing peaks than SMRT/NCOR,
suggesting that it may have BCL6-independent functions (Fig-
ure 1C). In contrast to BCL6-SMRT, BCL6-BCOR complexes
weremore frequently localized to promoters (Figure 1B). Consis-
tent with previous studies (Ci et al., 2009), BCL6 corepressor
peaks contain binding sites for other transcription factors,
including STAT sites (which overlap with BCL6 motif; Dent
et al., 1997) RUNX1 and ELK1, which might either compete or
cooperate with BCL6. BCOR-BCL6 peaks were preferentially
enriched in CG-rich sequences, consistent with their frequent
localization in CpG islands (35%; 1,830/5,265 peaks). On the
other hand, BCL6-SMRT peaks were preferentially enriched in
MEF2A motifs (Figure S2B). Notably, 13% of BCL6 binding sites
contain both SMRT and BCOR peaks, suggesting that BCL6
may simultaneously recruit both corepressors at certain BCL6
binding sites (Figure 1C).
We also performed ChIP-seq for BCL6, SMRT, NCOR, and
BCOR in purified primary humanGCB cells, fromwhich DLBCLs
arise (Figures S2C, S2D, S2G, and S2H). Seventy-eight percent
of BCL6 target genes in DLBCL cells overlapped with GCB cells,
and 85% of target genes with BCL6-corepressor complexes in
DLBCL also contained such complexes in GC B cells, although
GC B cells also have additional unique targets (Figure S2E and
S2F). Most importantly, the genome-wide distribution of BCL6
and corepressors was highly similar to DLBCL cells with compa-
rable distributions to promoters and intergenic/intronic regions
and 90% overlap of SMRT with BCL6 (Figure S2G and S2H).
These results suggest that recruitment of these corepressors
may be just as vital for normal GC B cells as for DLBCL
cells. Confirming this hypothesis, knockin mice expressing a
BCL6N21KH116A lateral groove mutant, which is unable to recruit
SMRT, NCOR, and BCOR but is otherwise normally expressed,
folded, and bound to target genes (Ahmad et al., 2003; Ghetu
et al., 2008), fail to form GCs (Figure S3A) (Huang et al., 2013).
BCL6 Forms SMRT/BCOR Ternary Complexes
to Potently Repress Expression
To understand the significance of BCL6 and corepressor distri-
bution patterns relative to gene expression, we initially focused
on BCL6 promoter complexes. BCL6 was bound to the pro-
moters of 3,140 genes in DLBCL cells, 71% of which were occu-
pied by overlapping BCL6-corepressor peaks. Overall, BCL6
binding sites at promoters could be classified into four classes:
(1) BCL6 only (n = 906), (2) BCL6-SMRT only (n = 92), (3)
BCL6-BCOR only (n = 1,783), and (4) BCL6-SMRT-BCOR (n =
341) (Figure S3B). At these latter sites, BCL6-SMRT-BCOR
were all colocalized, suggesting that these are BCL6-dependent
ternary complexes. The requirement of BCL6 to recruit BCORCell Reports 4, 578–588, August 15, 2013 ª2013 The Authors 579
Figure 1. Genome-wide Distribution of BCL6 and Corepressors BCOR, SMRT, and NCOR in DLBCL Cells
(A) Tumor growth plot in DLBCL xenograftedmice (Farage cell line) after treatment with RI-BPI versus control peptide (50mg/kg/day for 5 consecutive days). Data
are represented as mean ± SEM.
(B) Genomic distribution of BCL6 peaks and BCL6 peaks coinciding with BCOR (BCL6-BCOR), SMRT (BCL6-SMRT), and NCOR (BCL6-NCOR) peaks based on
their location relative to RefSeq transcripts (hg18) in OCI-Ly1 cells.
(C) Venn diagrams representing the overlap of BCL6, BCOR, and SMRT ChIP-seq peaks in DLBCL cells.
(D) GSEA analysis integrating ChIP-seq and mRNA-seq results after BCL6 knockdown. The enrichment of promoter target genes bound by BCL6 ternary
complexes (BCL6-BCOR-SMRT), BCL6-BCOR only, BCL6-SMRT only, or BCL6 only was tested based on decreasing gene all expression log ratios (48 hr;
siBCL6/siNT). Weighed statistic and 5,000 sample permutations were used. NES, normalized enrichment score; FDR, false discovery rate.
(E) Pathway analysis comparing BCL6-BCOR only target genes versus BCL6-ternary target genes that were upregulated more than 1.5-fold after BCL6
knockdown.
See also Figures S1, S2, S3, S4, and S5 and Table S1.and SMRT was confirmed by performing ChIP assays at repre-
sentative promoters (PRDM1, TLR4, and CD69) 24 hr after
BCL6 or control small interfering RNA (siRNA) transduction in
DLBCL cells. Recruitment of both corepressors was reduced
proportionally to BCL6 depletion (Figure S3C).
To determine the relative contribution of these different BCL6
complexes to gene expression, we performed messenger RNA
sequencing (mRNA-seq) at 24 hr and 48 hr after transduction of
BCL6 or control siRNA in DLBCL cells (Figures S4A and S4B).
Derepression of BCL6 promoter target genes was the dominant
effect after BCL6knockdown (approximately 70%of genes upre-
gulated). We used gene set enrichment analysis (GSEA) to deter-
minewhich type of BCL6 complex (BCL6only, BCL6-BCORonly,
BCL6-SMRT only, and BCL6-SMRT-BCOR) was most strongly
associated with gene derepression (Figure 1D). This analysis re-580 Cell Reports 4, 578–588, August 15, 2013 ª2013 The Authorsvealed strong enrichment of BCL6 ternary complex (BCL6-
SMRT-BCOR) among derepressed genes (false discovery rate
[FDR] = 0.002). BCL6-BCOR only promoters were mildly en-
riched in derepressed genes with only a trend toward statistical
significance (FDR = 0.088). Genes bound by BCL6-SMRT only
or BCL6 without corepressors were not significantly affected
by BCL6 depletion (FDR = 0.22 and FDR = 0.99, respectively).
Accordingly, BCL6 ternary complex genes were more signifi-
cantly derepressed when compared with BCL6-only, BCL6-
SMRT only, or BCL6-BCOR only complexes (p = 0.0026, p =
0.0014, and p= 0.019, respectively;Mann-Whitney) (Figure S4C).
Similar effects were observed at both 24 and 48 hr (Figures S4D
and S4E). These results were confirmed in three additional inde-
pendent mRNA-seq experiments in DLBCL cells after BCL6
versus control siRNA knockdowns (Figure S5). Derepressed
Figure 2. BCL6 Can Recruit Both BCOR
and SMRT Corepressor Complexes Simul-
taneously through Homodimerization of its
BTB Domain in Promoters
(A and B) BCL6 binding (green) at the promoters
of CD69 and BANK1 coincides with binding of
corepressors BCOR (blue) and SMRT (red),
respectively. y axis values represent read den-
sities normalized to total number of reads.
(C) ChIP-re-ChIP assay in BCL6-BCOR-SMRT
promoters using BCOR and SMRT antibodies. IgG
was used as a negative control. A BCL6 intron 9
locus is shown as a negative control. The experi-
ment was performed in duplicate using triplicate
wells. The y axis represents enrichment as %
input ± SEM.
(D) FRET assay for A488-BCOR and BODIPY-
SMRT peptides in solution with BCL6 BTB.
Fluorescence (AU) is shown as a function of
increasing BCL6 BTB concentration. FRET
emission is generated when both peptides bind
to the BCL6 BTB dimer. Higher concentrations of
BCL6 BTB dimers increase single peptide bind-
ing events decreasing FRET emission. Error bars
indicate SD.
(E) Hybrid model of the BCL6 BTB dimer (each
monomer in violet and pink) simulated in com-
plex with two peptides corresponding to BCOR
498-514 (green) and SMRT 1414-1430 (cyan)
used in the FRET assay.
See also Figure S6.genes with BCL6 ternary complexes were also most significantly
enriched in gene categories linkedwith the canonical and biolog-
ically validated BCL6 functions (Basso et al., 2004; Ci et al.,
2009), including B cell differentiation, B cell activation, DNA repli-
cation, genes induced by STAT3 (Lam et al., 2008), and genes
repressed by BCL6 in independent data sets (Shaffer et al.,
2000) (Figure 1E). Hence, ternary promoter complexes are
most strongly linked to active repression by BCL6 and to canon-
ical BCL6 biological functions.
BCL6 forms an obligate homodimer with two symmetric lateral
grooves and so could theoretically bind to BCOR and SMRT
simultaneously. To determine if BCL6 forms a true ternary com-
plex, we performed sequential ChIP (ChIP-re-ChIP) using BCOR
or SMRT antibody followed by a second immunoprecipitation
switching the two antibodies or using immunoglobulin G (IgG)
control. We then performed quantitative PCR (qPCR) to enrich
promoter binding sites with overlapping BCL6/BCOR/SMRT
peaks (CD69, BANK1, PRDM1, TLR4, and CCR6 shown in Fig-
ures 2A, 2B, and S6A). In each case, sequential immunoprecip-
itation enriched these loci consistent with formation of ternary
BCL6-SMRT-BCOR complexes (Figure 2C). As a positive con-
trol, we performed ChIP-re-ChIP with BCL6 antibody followed
by BCOR or SMRT ChIP (Figure S6B). To further confirm ternary
binding, we performed fluorescence resonance energy transfer
(FRET) assays in which the BCL6 BTB homodimer (Stogios
et al., 2005) and fluorescent BCOR and SMRT BCL6 binding
polypeptides were placed together in solution (Ahmad et al.,
2003; Ghetu et al., 2008). This experiment resulted in a FRETsignal, indicating that BCOR and SMRT fragments bind simulta-
neously to the homodimer (Figure 2D), as illustrated in Figure 2E.
At higher concentrations of BCL6 BTB dimer, the majority of the
peptides exist as single corepressor peptide/BCL6 BTB com-
plexes, which produce no FRET signal (Figure 2D). Hence, the
BCL6 BTB dimer is able to coordinate assembly of a multifunc-
tional ternary corepressor complex at gene promoters including
both the PRC1-like BCOR and the HDAC3-containing SMRT
complex.
BCL6 Repression Is Linked to Specific Chromatin States
and RNA Polymerase II Pausing
In order to understand the chromatin context within which BCL6
is functional as a repressor, we performed ChIP-seq for the
H3K4me3, H3K9ac, H3K79me2, and H3K36me3 activation
marks and the H3K27me3 repressive mark and enhanced
reduced representation bisulfite sequencing (ERRBS) for cyto-
sinemethylation in DLBCL cells. We then used an unbiased anal-
ysis approach (multidimensional principal component analysis)
to group gene promoters according to the naturally occurring
binding patterns of BCL6, corepressors, histone modifications,
and cytosinemethylation (Figure 3A). We found that genes linked
to principal component 2 (PC2) featured significantly lower tran-
script levels in DLBCL cells (p < 13 108) and, most importantly,
significant derepression after BCL6 siRNA (p < 1 3 108; Fig-
ure 3B). PC2 promoters were significantly enriched for BCL6,
SMRT, and BCOR as well as repression marks H3K27me3 and
cytosine methylation but at the same time were markedlyCell Reports 4, 578–588, August 15, 2013 ª2013 The Authors 581
Figure 3. Potent BCL6 Repression Occurs within Repressed
Chromatin States and Is Linked to RNA Pol II Pausing
(A) Graphical representation of weighted PCA analysis integrating histone
mark and DNA methylation enrichment levels surrounding all TSSs. The top
two PCs are shown. The color key indicates the weights of the original vari-
ables assayed by ChIP-seq and ERRBS.
(B) Correlation of genes corresponding in each PC with basal levels of gene
expression and gene expression changes after BCL6 knockdown (48 hr) is
indicated.
(C) Cumulative distribution of RNA Pol II pausing ratios (calculated as the
fraction of normalized read density ratio of Ser5-P Pol II (paused) around the
TSS (100 to +200 bp) to the Ser2-P Pol II (elongating) density at the TES
(TES +2 kb) comparing BCL6 target genes upregulated after BCL6 siRNA
versus the rest of BCL6 target genes. p value is indicated.
See also Figure S7.depleted of all four active histone marks. In contrast, PC1
captured active genes associated with binding but not repres-
sion by BCL6. Overall, the principal component analysis (PCA)
analysis indicated that only promoters with ternary complexes
plus a completely repressed chromatin configuration are actively
repressed by BCL6. BCL6 does not appear to be functionally
significant at promoters with activation marks or where BCL6
is not forming a ternary complex.
Analysis of promoter ChIP-seq profiles further indicated that
BCL6 binding occurred within the nucleosome-free region
(NFR) located just upstream of the transcriptional start site
(TSS) as revealed by the valley of low H3K4me3 abundance (Fig-
ure S7A). SMRT and BCOR were precisely overlapped with
BCL6 except that BCOR extended further downstream of the
TSS, where RNA polymerase II (RNA Pol II) is localized in DLBCL
cells. Indeed, ChIP-seq for paused (phosphoSer5) and elon-
gating (phosphoSer2) RNA Pol II in DLBCL cells revealed that
BCL6-repressed genes had a significantly higher paused versus
elongating Pol II ratio compared to nonrepressed BCL6 targets
(p < 1 3 108; Figures 3C and S7C). This was independently
confirmed by analyzing the distribution of total RNA pol II by
ChIP-seq in DLBCL cells (p < 13 108; Figure S7B). Altogether,
potent BCL6 repression of promoters in B cells is linked to
ternary BCL6-SMRT-BCOR corepressor complex formation582 Cell Reports 4, 578–588, August 15, 2013 ª2013 The Authorswithin a specific chromatin context featuring loss of activating
and gain of repressivemarks and suppression of RNA Pol II elon-
gation but not Pol II recruitment (Figure S7D).
BCL6-SMRT Complexes Inactivate B Cell Enhancers
to Repress Proximal Gene Expression
Most BCL6-SMRT binding (85%) occurred outside of promoters,
suggesting that the BCL6 mechanism may differ at these sites
and is perhaps linked to enhancer regions (Figure 4A). Enhancers
are characterized by the presence of H3K4me1 and absence of
H3K4me3 (Heintzman et al., 2007, 2009). We therefore per-
formed H3K4me1 ChIP-seq to map enhancer regions in DLBCL
cells. The vast majority of BCL6-SMRT distal/intronic peaks
were H3K4me3NEG/H3K4me1POS (n = 2,162), suggesting that
these complexes are within transcriptional enhancers (Fig-
ure 4A). We first focused on distal BCL6-SMRT enhancer binding
sites (n = 818, >5 kb away from TSSs). BCL6 and SMRT peak
summits were precisely colocalized at enhancers and generally
restricted to a narrow region of less than 400 bp framed by two
adjacent nucleosomes as indicated by H3K4me1 read density
(Figure 4B). These BCL6-SMRT enhancers were significantly
conserved as compared to adjacent control regions, which is
suggestive of their functional relevance (Figure S8A).
We next examined whether BCL6-SMRT binding to en-
hancers has a cis-regulatory function. Since most BCL6-SMRT
enhancers were located within 80 kb from the nearest transcript
(Figure S8B), we identified the most proximal gene for every
BCL6-SMRT distal enhancer (n = 553). Using GSEA, we found
that the group of genes with BCL6-SMRT-bound enhancers
were significantly enriched in genes derepressed after BCL6
knockdown (FDR = 0.005 at 24 hr and FDR = 0.03 at 48 hr;
Figures 4C and S8C). In contrast, genes associated with distal
enhancers bound by BCL6 without SMRT (n = 654) were not
enriched among BCL6 siRNA-derepressed genes (FDR = 0.38
at 24 hr and FDR = 0.68 at 48 hr; Figures 4C and S8C). Similarly,
BCL6-SMRT enhancer linked genes (but not BCL6 only) were
significantly upregulated after BCL6 knockdown (BCL6-SMRT:
p < 0.0001 at 24 hr and p = 0.032 at 48 hr; BCL6 only: p = 0.07
at 24 hr and p = 0.49 at 48 hr; Mann-Whitney U) compared to
control genes (Figures 4D and S8D).
To further investigate whether BCL6 can repress through
enhancer binding we performed reporter assays using con-
structs containing a BCL6-SMRT enhancer identified by our
ChIP-seq, located 13 kb upstream of the CDKN1A promoter
and containing a BCL6 consensus binding motif (Figures 4E
and S8E). Addition of CDKN1A distal enhancer induced 3-fold
repression of CDKN1A promoter when transfected in DLBCL
cells, and this repressor activity was markedly attenuated by
BCL6 knockdown (p < 0.0001, Mann-Whitney U; Figure 4F).
Enhancer with mutated BCL6 binding site was unable to repress
luciferase activity and instead enhanced CDKN1A promoter
activity (Figure 4F). BCL6 knockdown did not induce higher
expression from the mutant reporter. In 293T cells, the CDKN1A
distal enhancer acted as an inducer of transcriptional activity
(Figure S8F). However, transfection of BCL6 (but not control
plasmid) suppressed this CDKN1A enhancer activity. Collec-
tively, these data support the notion that BCL6 can repress
enhancer elements.
Figure 4. BCL6-SMRT Complexes Mediate
Enhancer Silencing
(A) Overlap of distal/intronic BCL6-SMRT peaks
with H3K4me3 and H3K4me1 peaks in DLBCL
cells.
(B) BCL6, SMRT, and H3K4me1,3 ChIP-seq read
density profiles in BCL6-SMRT enhancers
centered at the BCL6 peak summit. y axis repre-
sents average read densities normalized to total
number of reads.
(C) GSEA analysis of genes proximal to BCL6-
SMRT-bound enhancers or BCL6 non-SMRT en-
hancers. Genes were ranked based on decreasing
log2 RPKM (siBCL6/siNT) at 48 hr BCL6 knock-
down (weighted p2 statistic, 5,000 permutations).
(D) Comparison of fold expression induction
(siBCL6/siNT RPKM, 48 hr) of genes proximal
to BCL6-SMRT enhancers or BCL6 non-SMRT
enhancers versus other genes.
(E) A BCL6-SMRT enhancer located 13 kb
upstream of CDKN1A is illustrated. UCSC tracks
of BCL6, SMRT, H3K4me1,3, and total RNA
polymerase II density normalized to the total
number of reads are represented. Location of
BCL6 sequence motifs is indicated.
(F) Reporter assays performed in DLBCL cells with
constructs containing CDKN1A promoter alone
(Prom), promoter and wild-type 13 kb enhancer
(Prom + WT Enh), or promoter and mutant
enhancer (Prom+ mut Enh). Cells were treated
with siBCL6 and siNT as indicated in quadrupli-
cates. y axis represents fold repression of reporter
based on relative luciferase (versus TK-Renlla)
compared to the basal activity of the promoter
construct. Data are represented as mean ±SEM.
See also Figure S8.BCL6 Recruitment of SMRT Deacetylates H3K27
to Repress Enhancers
Active enhancers can be distinguished from inactive or ‘‘poised’’
enhancers based on the presence of H3K27 acetylation
(Creyghton et al., 2010;Rada-Iglesias et al., 2011).Weperformed
H3K27ac ChIP-seq in DLCBL cells and observed that also in
these cells, enhancers with high levels of H3K27ac are associ-
ated with highly expressed genes whereas enhancers with low
H3K27ac level are associated with lower gene expression (p <
0.0001, Mann-Whitney U; Figure S9A). Given the role of
H3K27ac in enhancer activation, we hypothesized that BCL6-
mediated recruitment of SMRT complex (which contains
HDAC3) might deacetylate H3K27, thus rendering these
enhancers inactive. Quantitative ChIP assays were performed
to detect H3K27ac at BCL6-SMRT enhancers, BCL6-only
enhancers, or control loci in DLBCL cells transfected with either
BCL6 or control siRNA. BCL6 knockdown increased the
relative abundance of H3K27ac at most BCL6-SMRT enhancers
but not at BCL6-only enhancers or control loci (Figure 5A).
Accompanying the increase in H3K27 acetylation, BCL6 siRNACell Reports 4, 578–588resulted in a reduction of SMRT recruit-
ment to BCL6-SMRT enhancers (Fig-
ure S9B), which paralleled the reduction
in BCL6 enrichment (Figure S9C).Because SMRT complexes contain HDAC3, we hypothesized
that this histone deacetylase mediates H3K27 deacetylation. We
therefore performed an in vitro HDAC assay using immunopre-
cipitated SMRT and HDAC3 complexes from DLBCL protein
extract incubated with bulk histones, followed by immunoblot-
ting for H3K27ac. This procedure yielded a marked decrease
in H3K27ac among histones incubated with SMRT or HDAC3
complexes but not in IgG control pull-downs (Figure 5B).
H3K27 deacetylation was abrogated by addition of the HDAC
inhibitor Trichostatin A (Figure 5B). To further explore the impact
of HDAC3 on H3K27 acetylation in B cells, we isolated splenic
B cells from mice with conditional B-lineage-specific deletion
of Hdac3 versus littermate controls. We confirmed reduction of
Hdac3 in conditionally deleted B cells by western blotting and
observed a reciprocal global increase of the H3K27ac compared
to B cells from control mice (Figure 5C).
To test whether disruption of the BCL6-SMRT complex could
toggle enhancers to an active state, we treated DLBCL cells with
the BCL6 small molecule inhibitor 79-61085, which blocks
recruitment of corepressors to the BTB domain (Cerchietti, August 15, 2013 ª2013 The Authors 583
Figure 5. BCL6 Recruits SMRT to Deace-
tylate H3K27, Leading to Enhancer Inacti-
vation
(A) Selected BCL6-SMRT bound enhancers or
BCL6 only enhancers were tested for enrichment
of H3K27ac by quantitative ChIP (qChIP) in OCI-
Ly1 cells nucleofected with siBCL6 or siNT. Rela-
tive enrichment is normalized to siNT and shown
as mean ±SEM.
(B) H3K27ac immunoblot of in vitro histone
deacetylation reactions using immunoprecipitated
SMRT and HDAC3 in the presence or absence of
TSA (Trichostatin A). IgG was used as a negative
immunoprecipitation control and H3 as a loading
control. Coomassie stain indicates that equal
amount of antibody was added in each immuno-
precipitate.
(C) H3K27ac immunoblot using whole cell extracts
of B220+ cells isolated from two Hdac3+/+/ROSA-
GFP/CD19-Cre and two Hdac3FL//ROSA-GFP/
CD19-Cre mice. Hdac3 depletion in null cells was
confirmed. H3 and b-globin were used as loading
controls.
(D) Biological replicates of H3K27ac qChIP per-
formed in triplicates in OCI-Ly1 cells exposed to
50 mM of 79-61085 or vehicle (DMSO) for 30 min.
Fold H3K27ac enrichment versus vehicle is shown
(y axis). Data are represented as mean ± SEM.
See also Figure S9.et al., 2010a). 79-61085 caused the induction of H3K27ac at
BCL6-SMRT enhancers but not at enhancers bound by BCL6
alone (Figure 5D). These effects are not due to loss of BCOR
since BCOR complex did not deacetylate H3K27 (Figure S9D),
nor did BCOR siRNA knockdown induce H3K27 acetylation
levels at BCL6 target enhancers Figures S9E and S9F). Collec-
tively, these data suggest that BCL6 recruitment of SMRT results
in HDAC3-dependent H3K27 deacetylation of enhancers and
gene silencing. By disrupting BCL6 corepressor complexes,
BCL6 inhibitors can reactivate the BCL6-repressed enhancer
network.
SMRT Corepressor Complexes Antagonize p300
Enhancer Acetylation and Activation
The p300 histone acetyltransferase (HAT) mediates H3K27 acet-
ylation and enhancer activation (Jin et al., 2011; Visel et al.,
2009). We hypothesized that BCL6-SMRT complexes would
antagonize enhancer activation by p300. We performed p300
ChIP-seq in DLBCL cells and identified a total of 988 p300-
bound enhancers. A total of 87% (856/988) of these enhancers
were H3K27acHIGH. We identified 369 enhancers with BCL6-
SMRT only, 449 with BCL6-SMRT and p300, and 250 with
BCL6-p300, raising the possibility that p300 and SMRT might
compete for control of certain BCL6 target enhancers. Indeed,
we observed significantly lower levels of H3K27ac in BCL6-
SMRT enhancers without p300 (p < 0.0001, Mann-Whitney U)
and significantly higher levels of H3K27ac in enhancers with
BCL6 and p300 but without SMRT (p < 0.0001) compared to
enhancers that were occupied by BCL6 with both SMRT and
p300 (Figure 6A).584 Cell Reports 4, 578–588, August 15, 2013 ª2013 The AuthorsIn order to more globally evaluate the equilibrium between
BCL6-SMRT complex and p300 on H3K27ac levels, we per-
formed H3K27ac ChIP-seq in cells treated with BCL6 or control
siRNA (Figure S10A). Consistent with a role for SMRT in antago-
nizing p300-mediated H3K27ac, BCL6-SMRT enhancers
without p300 displayed a greater increase in H3K27ac (p <
0.0001, Mann Whitney U) compared to BCL6-SMRT enhancers
that also contained p300 (Figure 6B). Moreover, BCL6-SMRT-
p300 enhancers in turn featured greater induction of H3K27ac
than BCL6 enhancers with p300 but without SMRT (p <
0.0001). The greater increase of H3K27ac levels, especially in
BCL6-SMRT enhancers, suggests that upon loss of BCL6-
SMRT binding, p300 complexes can more efficiently acetylate
H3K27.
As a complementary and unbiased approach to determine the
link between gene expression and enhancer BCL6 complexes,
we performed a multidimensional PCA of distal enhancer BCL6
peaks. Genes associated with one principal component (PC3,
n = 715 genes) were notably derepressed upon BCL6 siRNA
(p < 1 3 108, t test). Consistent with the above data, PC3
featured strong enrichment of BCL6, SMRT, and H3K4me1 but
no enrichment for H3K27ac or p300 (Figure 6C). In contrast,
PC1 and PC2 genes contained enhancer BCL6 complexes
plus p300 with or without enhancer marks, respectively, and
were not strongly associated with genes repressed by BCL6.
We repeated these analyses on the intronic BCL6-SMRT
enhancers (n = 1,344) and observed a comparable association
of BCL6-SMRT intronic enhancers with gene derepression,
p300 binding, and H3K27ac levels (Figures S10B–S10E).
These data were validated using independent BCL6 siRNA
Figure 6. BCL6-SMRT Complexes Antago-
nize p300 Acetyltransferase Activity to
Mediate Enhancer Toggling
(A) Comparison of the average normalized
H3K27ac read density levels in BCL6 enhancers
bound by SMRT but not p300, bound by both
SMRT and p300 or bound by p300 but not SMRT.
(B) Log2 change of H3K27ac levels upon BCL6
knockdown inBCL6enhancersboundbySMRTbut
not p300, bound by both SMRT and p300 or bound
by p300 but not SMRT. p values are indicated.
(C) Graphical representation of weighted PCA
analysis using distal BCL6 binding sites. Correla-
tion with gene expression changes after BCL6
depletion (24 hr) links PC3 (715 distal enhancers,
p < 13 108) to gene derepression. The color key
indicates the weights of the original variables
assayed by ChIP-seq.
See also Figures S10, S11, S12, S13, and S14.knockdown RNA-seq replicates as well as additional enhancer
histone mark ChIP-seq data sets including H3K4me2, which
also marks enhancer regions (Ernst et al., 2011) (Figures S11
and S12). These results suggest that BCL6 recruitment of
SMRT/HDAC3 complexes to distal and intronic enhancer
regions represses gene expression by deacetylating H3K27ac
and opposing the actions of p300 HAT complexes.
Altogether, the data suggest that BCL6 mediates its key bio-
logical effects in B cells through at least two biochemically
distinct BTB domain-dependent transcriptional repression
mechanisms, repressing promoters most potently through
multifunctional ternary complexes containing BCOR and SMRT
and repressing enhancers through SMRT-HDAC3 actions on
H3K27ac (Figure 7). Both of these functions can be therapeuti-
cally targeted by BCL6 BTB domain peptide and small molecule
inhibitors to kill DLBCL cells or suppress GC formation. Indeed
exposure of DLBCL cells to RI-BPI resulted in the same preferen-
tial derepression of BCL6 ternary complex promoters and BCL6-
SMRT enhancer-associated genes, as observed with BCL6
siRNA (Figure S13).
DISCUSSION
Herein, we report a unique mechanism through which a single
transcription factor can serve as scaffold for recruiting structur-
ally and functionally distinct chromatin-modifying complexes
through binding to identical surface motifs. We show that
BCL6 simultaneously recruits both BCOR and SMRT/NCOR
corepressors to symmetrical lateral grooves to form a ternary
core repressor complex with BCL6 BTB domain homodimers,
yet SMRT and BCOR differ in their disposition around BCL6-
regulated promoters. SMRT localizes focally with BCL6 at
nucleosome-free regions, whereas BCOR tends to spread
downstream of the transcription start site. BCOR downstream
spreading may be linked to our observation that BCL6 sup-
presses RNA Pol II elongation more than preventing loading of
Pol II complexes. Repression through promoter ternary com-
plexes is functionally linked to specific epigenetic chromatin
marks associated with corepressor enzymatic activities (Gear-
hart et al., 2006; You et al., 2013).At enhancers, BCL6-SMRT complexes mediate silencing
through a mechanism involving HDAC3 deacetylation of
H3K27. SMRT recruitment appears to compete with enhancer
activation mediated by p300 through H3K27 acetylation, thus
providing a basis for dynamic and reversible ‘‘toggling’’ of en-
hancers. This would be different from the effect of the histone
demethylase LSD1, which permanently erases enhancers
through H3K4 demethylation (Whyte et al., 2012). Nonetheless,
it remains to be investigated how H3K27 acetylation is linked
to enhancer activity. Enhancer toggling may play a physiological
role in enabling recycling of B cells between the dark zone and
light zone of GCs. Transient interactions with T cells in the light
zone triggers CD40 and mitogen-activated protein kinase
(MAPK) signaling in B cells, which phosphorylates and delocal-
izes SMRT and NCOR to the cytoplasm, leading to reversible
derepression of BCL6 targets (Polo et al., 2008; Ranuncolo
et al., 2007). Presumably, CD40 toggling of BCL6 enhancers
enables B cells to become competent for terminal differentiation
if they have generated a high-affinity immunoglobulin or to
undergo apoptosis if they are damaged or unable to form high-
affinity antibody. Toggling back to the repressed state permits
recycling of B cells to the dark zone for additional rounds of
affinity maturation. Along these lines, it was shown that once
CD40 signaling is disengaged, SMRT returns to BCL6 and
BCL6 target gene repression is restored (Polo et al., 2008). In
support of this notion, analysis of genes that are upregulated in
GC light zone B cells (centrocytes) as compared to dark zone
cells (centroblasts) (Caron et al., 2009) show significant upregu-
lation of GC B cell BCL6-SMRT enhancer-related target genes
but not BCL6-only enhancer genes (p < 0.0001, Mann Whitney
U; Figures S14A and S14B). BCL6-SMRT enhancer targets
were also significantly enriched among centrocyte-upregulated
genes (FDR = 0.006, GSEA). Moreover, CD40 signaling and
MAPK pathways are strongly enriched among genes regulated
by BCL6-SMRT enhancer complexes (Figure S14C).
Enhancer toggling may be pathologically suppressed in
certain DLBCLs containing EP300-inactivating mutations
(Cerchietti et al., 2010b; Pasqualucci et al., 2011). Reduction in
EP300 function could tip the balance of transcriptional repres-
sion in favor of BCL6-SMRT complexes and thus favor theCell Reports 4, 578–588, August 15, 2013 ª2013 The Authors 585
Figure 7. Model of the BCL6 Repression
Mechanism
BCL6 dimers can simultaneously recruit PRC1-
like BCOR complexes and HDAC3-containing
SMRT complexes in B cell promoters to most
effectively repress transcription in a repressed
chromatin environment. Alternatively, BCL6
selectively recruits SMRT to functionally inactivate
a network of B cell enhancers through H3K27
deacetylation, opposing the effect of p300 com-
plexes that mediate H3K27 acetylation. BCL6 BTB
inhibitors dismiss BCOR and SMRT complexes
and reactivate the BCL6-targeted gene programs,
thereby killing lymphoma cells while BCL6-BTB
point mutations abrogate GC formation.oncogenic effects of BCL6. BCL6 BTB blockade was sufficient
to induce H3K27ac levels at BCL6-SMRT target enhancers.
Hence, enhancer toggling by BCL6 inhibitors may contribute to
their antilymphoma effects (Figure 7).
BCL6 ternary complex and BCL6 enhancer complexes seem
to be independent of each other, since there was no trend
toward overlap at the same genes (p = 0.957) and no tendency
for the small set of overlapping promoter-enhancer complex-
containing genes to be more derepressed after BCL6 siRNA
(p = 0.44, Mann Whitney test, data not shown). Specific BCL6
target gene sets may thus be independently controlled through
its two different BTB-domain-dependent repression mecha-
nisms. Collectively the BTB-dependent mechanisms we identi-
fied are essential for DLBCLs and the normal GC B cells from
which they are derived (e.g., as in Figures 1A and S3A). However,
our data do not rule out that other BCL6 repression mechanisms
may exist and contribute in some way to its actions in B cells or
other cell types (Mendez et al., 2008; Parekh et al., 2007). Further
research into the biochemistry of BCL6 in B cells and other cell
types is warranted to explore this question. It is notable that
BCL6 was also shown to be localized at enhancers in macro-
phages (Barish et al., 2012). However, BCL6 functions at macro-
phage enhancer actions are likely mechanistically different than
B cells since BTB-domain-dependent corepressor recruitment
is dispensable for the actions of BCL6 in this cell type (Huang
et al., 2013).
In summary, our data highlight the flexibility of BCL6 to
simultaneously regulate gene expression through different586 Cell Reports 4, 578–588, August 15, 2013 ª2013 The Authorsmechanisms on different gene sets
within the same cells, through the same
protein interface. From the immunology
perspective, it is notable that these
mechanisms are specifically significant
to B cells but may not play a major
role in the actions of BCL6 in T cells
or macrophages (Huang et al., 2013).
Hence, BCL6 displays a tremendous
degree of flexibility and complexity in
the immune system. Importantly, thera-
peutic targeting of BCL6 with inhibitors
that block the BTB lateral groove results
in simultaneous blockade of both BTB-dependent mechanisms but has no effect on other compart-
ments of the immune system. This enables cell-type-specific
inhibition of BCL6 in lymphomas and B cells without needing
to resort to complicated tissue-specific delivery systems.
Finally, although our current studies have focused on BCL6, it
is likely that enhancer toggling and biochemical functional
diversity are more general mechanisms relevant to other
enhancer transcription factors.
EXPERIMENTAL PROCEDURES
All procedures involving animals were approved by the Animal Institute Com-
mittee at the Weill Cornell Medical College of Cornell University.
Chromatin Immunoprecipitation
OCI-Ly1 or purified GC B cells were fixed, lysed, and sonicated to generate
fragments less than 400 bp. Sonicated lysates were incubated with anti-
bodies overnight (see Extended Experimental Procedures), and after
increasing stringency washes immunocomplexes were recovered and DNA
was isolated. ChIP and input DNA was used in qPCR reactions to estimate
relative enrichment. In experiments using drug treatments (Figure 5D), cells
were treated with compounds (50 mM) for 30 min and after completion of
the assay ChIP and input DNA was quantified using Qubit 2.0 fluorometer
(Invitrogen) so that an equal amount of DNA was added to each PCR
reaction.
Details regarding the antibodies and primers used in this study can be found
in the Extended Experimental Procedures and in Tables S2, S3, and S4.
ChIP-re-ChIP
Experiments were performed as above. After the first round of ChIP,
immunocomplexes were eluted by incubating the beads in 50 ml TE buffer
supplemented with 10 mM DTT and protease inhibitors for 30 min at 37C
rocking. The eluted immunocomplexes were diluted up to 1 ml with dilution
buffer (1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl [pH 8.1], 150 mM
NaCl, and protease inhibitors) and antibodies were added for a second round
of ChIP. Finally, the bound DNA was eluted and enrichment was quantified by
qPCR of PCR products.
ChIP-Seq
ChIP-seq libraries were prepared using the Illumina ChIP-seq Library
preparation kit following the manufacturer’s instructions with minor
modifications starting with 10 ng of purified ChIP DNA (see Extended Experi-
mental Procedures). An input chromatin control library was generated for
each ChIP-seq experiment starting from the same amount of material and
was used as a negative control for peak calling and downstream analyses
using the ChIPseeqer package (Giannopoulou and Elemento, 2011). Details
on Illumina data analysis can be found in the Extended Experimental
Procedures.
Gene Expression Analysis by mRNA-Seq
A total of 3 mg of total RNA was isolated from at 24 hr and 48 hr after siRNA
nucleofection. The RNAeasy Plus Kit (QIAGEN) that included a genomic
DNA elimination step was used for RNA isolation. RNA concentration and
purity were determined using Nanodrop (Thermo Scientific) and integrity
was verified using Agilent 2100 Bioanalyzer (Agilent Technologies). Libraries
were generated using an mRNA-seq sample prep kit (Illumina). Briefly,
mRNA was selected by two rounds of purification using magnetic polydT
beads and then fragmented. First-strand synthesis was performed using
random oligos and SupersciptIII (Invitrogen). After second-strand synthesis,
a 200 bp paired-end library was prepared following the Illumina paired-end
library preparation protocol.
Statistical Analysis
The two-tailed Mann-Whitney U test was used unless otherwise stated. For
details on PCA analysis, see the Extended Experimental Procedures. All statis-
tical analyses were carried out using Prism software (Graphpad) and the R sta-
tistical package.
ACCESSION NUMBERS
The Gene Expression Omnibus (GEO) accession number for the ChIP-seq and
RNA-seq data sets reported in this paper is GSE29282. Additional ChIP-seq
data were analyzed that we previously reported under accession number
GSE43350.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures,
fourteen figures, and four tables and can be found with this article online at
http://dx.doi.org/10.1016/j.celrep.2013.06.016.
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